{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:34Z","timestamp":1786650094313,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>We report a case of a 32-year-old lady with chronic myeloid leukemia (CML) on Imatinib for the past four years and in complete clinical, hematological and molecular remission who presented to us with sudden onset of headache, vomiting and diplopia following self discontinuation of Imatinib for a month. Investigations were suggestive of chronic phase CML (CML-CP) with massive thrombocytosis and magnetic resonance imaging (MRI) of the brain revealed subdural hematoma. Coagulation studies confirmed the diagnosis of Acquired von Willebrand disease (AvWD) 2A because of thrombocytosis. The patient also tested positive for mutation T315I in bcr-abl gene. Treatment of the patient with high dose of Imatinib and hydroxyurea led to normalisation of platelet counts, reversal of coagulation defect and subsidence of symptoms. The present case highlights the importance of diagnosis of AvWD to determine the cause of bleeding in CML and distinguish it from Imatinib-induced bleeding, as prompt treatment with Imatinib can achieve reversal of the condition.<\/jats:p>","DOI":"10.4103\/0973-1482.146136","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:48:49Z","timestamp":1455842929000},"page":"1022-1022","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A rare case of chronic myeloid leukemia with acquired von Willebrand disease presenting as subdural hematoma"],"prefix":"10.4103","volume":"11","author":[{"given":"Ankur","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Medicine, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","first-page":"777","article-title":"Dural metastases in chronic myeloid leukemia presenting as subdural hematoma","volume":"22","author":"Prasad","year":"2012","journal-title":"Turk Neurosurg"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1080\/10428190310001615666","article-title":"Subdural hematomas during CML therapy with imatinib mesylate","volume":"45","author":"Song","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5045\/kjh.2010.45.1.73","article-title":"A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib Mesylate","volume":"45","author":"Kim","year":"2010","journal-title":"Korean J Hematol"},{"key":"R4-20260109","first-page":"117","article-title":"Acquired Von Willibrand Disease in Hematologic Malignancies at the National Cancer Institute (NCI) Egypt","volume":"12","author":"Assem","year":"2000","journal-title":"J Egypt Natl Cancer Inst"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0037-1613993","article-title":"Acquired von Willibrand syndrome: From pathophysiology to management","volume":"84","author":"Veyradier","year":"2000","journal-title":"Thromb Haemost"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.leukres.2009.05.011","article-title":"Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia","volume":"33","author":"Uchiyama","year":"2009","journal-title":"Leuk Res"},{"key":"R7-20260109","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"Itonaga","year":"2012","journal-title":"Int J Hematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:08Z","timestamp":1786647728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.146136","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}